Atrasentan in Patients With IgA Nephropathy

Inclusion Criteria

• •Double-Blind period:
• •Biopsy-proven IgA nephropathy.
• •Receiving a maximally tolerated dose of RAS inhibitor therapy (ACEi or ARB) that has been stable for at least 12 weeks. Exceptions from this requirement will be made for subjects who are unable to tolerate RAS inhibitor therapy.
• •Total urine protein ≥1 g/day as measured via 24-hour urine collection by central laboratory at Screening.
• •eGFR of at least 30 mL/min/1.73 m\^2 at Screening based on the CKD-EPI equation.
• •Willing and able to provide informed consent and comply with all study requirements.
• •SGLT2i Stable Stratum Only - Receiving a stable dose of an SGLT2i (per Investigator choice) in addition to a maximally tolerated and optimized dose of a RAS inhibitor that has been stable for at least 12 weeks prior to Screening.
• •All fertile men and WOCBP who engage in heterosexual intercourse must be willing to abide with highly effective forms of contraception, as specified in the protocol, throughout the study and for 1 month afterward. In WOCBP, use of contraceptive agents must have been started at least 1 month prior to Baseline.
• •Open-Label Period:
• •Willing and able to provide informed consent and comply with all OL extension study visits and study procedures.
• •Completed treatment through Week 132 and completed the Week 136 visit.
• •All fertile men and WOCBP who engage in heterosexual intercourse must be willing to abide with highly effective forms of contraception, as specified in the protocol, throughout the study and for 1 month afterward. In WOCBP, use of contraceptive agents must have been continued after completing the double-blind portion of the study.